WASHINGTON, Aug. 25, 2016 /PRNewswire-USNewswire/ -- Pharmaceutical Care Management Association (PCMA) President
"It was a mistake for
Mylan is simply the latest drugmaker trying to re-frame a pricing problem into a coverage problem. Blaming payers for these massive prices hikes is a red herring and doesn't pass the laugh test with policymakers.
Doubling down on 'bait and switch' copay offset tactics only further sticks consumers and payers with the tab. There's a reason that copay coupons—for hospitals, doctors and prescription drugs—are banned in public programs like Medicare as illegal 'kickbacks.'
Accusations that EpiPen copay levels have increased in retaliation to these latest price hikes are flatly untrue."
PBMs are projected to save employers, unions, government programs, and consumers $654 billion — up to 30 percent — on drug benefit costs over the next decade.
Potential solutions for high drug prices that policymakers could consider include:
PCMA is the national association representing America's pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, managed Medicaid plans, and others.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mylans-adoption-of-the-valeant-turing-blame-the-victim-strategy-will-not-pass-the-laugh-test-in-washington-300318484.html
SOURCE Pharmaceutical Care Management Association
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All